Children with acute lymphoblastic leukaemia Cancer
Conditions
Interventions
Anthropometry (data collection: T0 baseline
T1 remission induction 6 weeks
T2 Consolidation 4 months
T3 maintenance 12 months)
Weight will be determined to the nearest 0.1 kg, with subjects dressed in light clothing or ward gown among patients, using a Model 880 electronic scale (Seca, Hamburg, Germ
T3 maintenance 12 months)
Body composition measurements will be performed with the InBody S10® (InBody Co., Ltd., Seoul, Korea). This multi-frequency, segmental impedance analyser requires height, wei
Sponsors
Great Ormond Street Hospital for Children NHS Foundation Trust
Eligibility
Sex/Gender
All
Age
4 Years to 16 Years
Inclusion criteria
Inclusion criteria: 1. Consented to partake in the study 2. Diagnosed with Acute lymphoblastic Leukemia 3. On vitamin D supplementation standard of practice when receiving corticosteroids 4. Aged 4 - 16 years
Exclusion criteria
Exclusion criteria: 1. 17 years old + 2. Neuro-muscular disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in body composition will be measured using 4-lead bioelectrical impedance at baseline, 6 weeks, 6 month and 12months. Additionally, a DEXA scan will also measure changes in body composition at baseline and 12 months to compare the two methods 2. Change in energy expenditure with be measured using indirect calorimetry at baseline, 6 weeks, 6 month and 12months 3. Change in nutrition intake will be measured using 4-day food diary and Nutritics nutritional analysis programme at baseline, 6 weeks, 6 month and 12months | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Contacts
Public ContactGraeme O'Connor
Outcome results
None listed